Adverse events and oncotargeted kinase inhibitors:
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Amsterdam
Academic Press
2017
|
| Schlagworte: | |
| Online-Zugang: | FAW01 URL des Erstveröffentlichers |
| Beschreibung: | Part I: General Aspects 1. Introduction 2. Protein and Lipid Kinases 3. Kinase Inhibitors 4. Adverse Events Part II: Oncotargeted Kinase Inhibitors 5. Imatinib 6. Gefitinib 7. Erlotinib 8. Sorafenib 9. Sunitinib 10. Dasatinib 11. Lapatinib 12. Nilotinib 13. Pazopanib 14. Vandetanib 15. Vemurafenib 16. Crizotinib 17. Ruxolitinib 18. Axitinib 19. Bosutinib 20. Regorafenib 21. Cabozantinib 22. Ponatinib 23. Dabrafenib 24. Trametinib 25. Adatinib 26. Idelalisib 27. Ibrutinib Part III: Overview 28. Kinase Inhibitors as Adverse Event Inducers 29. Kinase Inhibitors as Drug Class Events 30. Conclusion and Perspectives |
| Beschreibung: | 1 online resource |
| ISBN: | 9780128094457 0128094451 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV045382350 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 181228s2017 |||| o||u| ||||||eng d | ||
| 020 | |a 9780128094457 |9 978-0-12-809445-7 | ||
| 020 | |a 0128094451 |9 0-12-809445-1 | ||
| 035 | |a (ZDB-33-ESD)ocn988219732 | ||
| 035 | |a (ZDB-33-EBS)ocn988219732 | ||
| 035 | |a (OCoLC)988219732 | ||
| 035 | |a (DE-599)BVBBV045382350 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-1046 | ||
| 082 | 0 | |a 616.994061 |2 23 | |
| 100 | 1 | |a Tridente, G. |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Adverse events and oncotargeted kinase inhibitors |c Giuseppe Tridente |
| 264 | 1 | |a Amsterdam |b Academic Press |c 2017 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Part I: General Aspects 1. Introduction 2. Protein and Lipid Kinases 3. Kinase Inhibitors 4. Adverse Events Part II: Oncotargeted Kinase Inhibitors 5. Imatinib 6. Gefitinib 7. Erlotinib 8. Sorafenib 9. Sunitinib 10. Dasatinib 11. Lapatinib 12. Nilotinib 13. Pazopanib 14. Vandetanib 15. Vemurafenib 16. Crizotinib 17. Ruxolitinib 18. Axitinib 19. Bosutinib 20. Regorafenib 21. Cabozantinib 22. Ponatinib 23. Dabrafenib 24. Trametinib 25. Adatinib 26. Idelalisib 27. Ibrutinib Part III: Overview 28. Kinase Inhibitors as Adverse Event Inducers 29. Kinase Inhibitors as Drug Class Events 30. Conclusion and Perspectives | ||
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Protein-tyrosine kinase / Inhibitors |2 fast | |
| 650 | 4 | |a Protein-tyrosine kinase $x Inhibitors | |
| 650 | 4 | |a Protein-tyrosine kinase |x Inhibitors |x Therapeutic use | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780128094006 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 0128094001 |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/book/9780128094006 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-33-ESD |a ZDB-33-EBS | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-030768683 | ||
| 966 | e | |u http://www.sciencedirect.com/science/book/9780128094006 |l FAW01 |p ZDB-33-ESD |q FAW_PDA_ESD |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804179234156969984 |
|---|---|
| any_adam_object | |
| author | Tridente, G. |
| author_facet | Tridente, G. |
| author_role | aut |
| author_sort | Tridente, G. |
| author_variant | g t gt |
| building | Verbundindex |
| bvnumber | BV045382350 |
| collection | ZDB-33-ESD ZDB-33-EBS |
| ctrlnum | (ZDB-33-ESD)ocn988219732 (ZDB-33-EBS)ocn988219732 (OCoLC)988219732 (DE-599)BVBBV045382350 |
| dewey-full | 616.994061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.994061 |
| dewey-search | 616.994061 |
| dewey-sort | 3616.994061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02160nmm a2200421zc 4500</leader><controlfield tag="001">BV045382350</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">181228s2017 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780128094457</subfield><subfield code="9">978-0-12-809445-7</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0128094451</subfield><subfield code="9">0-12-809445-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-33-ESD)ocn988219732</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-33-EBS)ocn988219732</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)988219732</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV045382350</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-1046</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tridente, G.</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adverse events and oncotargeted kinase inhibitors</subfield><subfield code="c">Giuseppe Tridente</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam</subfield><subfield code="b">Academic Press</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Part I: General Aspects 1. Introduction 2. Protein and Lipid Kinases 3. Kinase Inhibitors 4. Adverse Events Part II: Oncotargeted Kinase Inhibitors 5. Imatinib 6. Gefitinib 7. Erlotinib 8. Sorafenib 9. Sunitinib 10. Dasatinib 11. Lapatinib 12. Nilotinib 13. Pazopanib 14. Vandetanib 15. Vemurafenib 16. Crizotinib 17. Ruxolitinib 18. Axitinib 19. Bosutinib 20. Regorafenib 21. Cabozantinib 22. Ponatinib 23. Dabrafenib 24. Trametinib 25. Adatinib 26. Idelalisib 27. Ibrutinib Part III: Overview 28. Kinase Inhibitors as Adverse Event Inducers 29. Kinase Inhibitors as Drug Class Events 30. Conclusion and Perspectives</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Protein-tyrosine kinase / Inhibitors</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein-tyrosine kinase $x Inhibitors</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Protein-tyrosine kinase</subfield><subfield code="x">Inhibitors</subfield><subfield code="x">Therapeutic use</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780128094006</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">0128094001</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.sciencedirect.com/science/book/9780128094006</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-33-ESD</subfield><subfield code="a">ZDB-33-EBS</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-030768683</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">http://www.sciencedirect.com/science/book/9780128094006</subfield><subfield code="l">FAW01</subfield><subfield code="p">ZDB-33-ESD</subfield><subfield code="q">FAW_PDA_ESD</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV045382350 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T08:16:37Z |
| institution | BVB |
| isbn | 9780128094457 0128094451 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-030768683 |
| oclc_num | 988219732 |
| open_access_boolean | |
| owner | DE-1046 |
| owner_facet | DE-1046 |
| physical | 1 online resource |
| psigel | ZDB-33-ESD ZDB-33-EBS ZDB-33-ESD FAW_PDA_ESD |
| publishDate | 2017 |
| publishDateSearch | 2017 |
| publishDateSort | 2017 |
| publisher | Academic Press |
| record_format | marc |
| spelling | Tridente, G. Verfasser aut Adverse events and oncotargeted kinase inhibitors Giuseppe Tridente Amsterdam Academic Press 2017 1 online resource txt rdacontent c rdamedia cr rdacarrier Part I: General Aspects 1. Introduction 2. Protein and Lipid Kinases 3. Kinase Inhibitors 4. Adverse Events Part II: Oncotargeted Kinase Inhibitors 5. Imatinib 6. Gefitinib 7. Erlotinib 8. Sorafenib 9. Sunitinib 10. Dasatinib 11. Lapatinib 12. Nilotinib 13. Pazopanib 14. Vandetanib 15. Vemurafenib 16. Crizotinib 17. Ruxolitinib 18. Axitinib 19. Bosutinib 20. Regorafenib 21. Cabozantinib 22. Ponatinib 23. Dabrafenib 24. Trametinib 25. Adatinib 26. Idelalisib 27. Ibrutinib Part III: Overview 28. Kinase Inhibitors as Adverse Event Inducers 29. Kinase Inhibitors as Drug Class Events 30. Conclusion and Perspectives MEDICAL / Pharmacology bisacsh Protein-tyrosine kinase / Inhibitors fast Protein-tyrosine kinase $x Inhibitors Protein-tyrosine kinase Inhibitors Therapeutic use Erscheint auch als Druck-Ausgabe 9780128094006 Erscheint auch als Druck-Ausgabe 0128094001 http://www.sciencedirect.com/science/book/9780128094006 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Tridente, G. Adverse events and oncotargeted kinase inhibitors MEDICAL / Pharmacology bisacsh Protein-tyrosine kinase / Inhibitors fast Protein-tyrosine kinase $x Inhibitors Protein-tyrosine kinase Inhibitors Therapeutic use |
| title | Adverse events and oncotargeted kinase inhibitors |
| title_auth | Adverse events and oncotargeted kinase inhibitors |
| title_exact_search | Adverse events and oncotargeted kinase inhibitors |
| title_full | Adverse events and oncotargeted kinase inhibitors Giuseppe Tridente |
| title_fullStr | Adverse events and oncotargeted kinase inhibitors Giuseppe Tridente |
| title_full_unstemmed | Adverse events and oncotargeted kinase inhibitors Giuseppe Tridente |
| title_short | Adverse events and oncotargeted kinase inhibitors |
| title_sort | adverse events and oncotargeted kinase inhibitors |
| topic | MEDICAL / Pharmacology bisacsh Protein-tyrosine kinase / Inhibitors fast Protein-tyrosine kinase $x Inhibitors Protein-tyrosine kinase Inhibitors Therapeutic use |
| topic_facet | MEDICAL / Pharmacology Protein-tyrosine kinase / Inhibitors Protein-tyrosine kinase $x Inhibitors Protein-tyrosine kinase Inhibitors Therapeutic use |
| url | http://www.sciencedirect.com/science/book/9780128094006 |
| work_keys_str_mv | AT tridenteg adverseeventsandoncotargetedkinaseinhibitors |